Dementia and Alzheimer Disease

James E. Galvin, MD, MPH, provided thoughts on the struggles to raise dementia literacy and awareness in underserved, rural, ethnically diverse populations through the ongoing pandemic.

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.

Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

Here's what is coming soon to NeurologyLive.

Both short and long sleep durations were associated with worse self-reported cognitive function and multiple lifestyle outcomes, suggesting a U-shaped association.

Older adults with CI were found to require a significantly higher number of visits during home health care episodes, particularly skilled nursing visits.

Two study authors provide commentary on data that suggests that offering clinicians more perspective into the individual patient experience can help inform care for those individuals with DRP.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.

The director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine discussed the topics and ideas that clinicians should look forward to at the 2021 International Congress on the Future of Neurology.

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.

AC Immune and Genentech announced that treatment with semorinemab, an investigational antitau antibody, in the phase 2 LAURIET study resulted in significant changes from baseline on ADAS-Cog11 scores.

This was the first time that progression of cognitive fluctuations in patients with Lewy body dementia had been systematically investigated using a clinical rating scale.

Cluster analysis classified 29.5% more of the sample with mild cognitive impairment compared to the Alzheimer’s Disease Research Center’s consensus diagnosis.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed projects dedicated towards improving dementia recognition and care within multicultural communities.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 27, 2021.

The director of the Brain Health Registry discussed advancements in AD, following the publication of a systematic review on the predictors of Aß.

The principal investigator of the Alzheimer’s Disease Neuroimaging Initiative discussed a study published earlier this year, which aimed at identifying better ways to predict dichotomous Aß.

The toolkit’s assays contain several biomarkers, including Aß 1-42, Aß 1-40, α-syn, GFAP, IL-6, neurogranin, NfL, phosphotau181, S100B, sTREM2, total tau, and YKL-40.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the real-world level of dementia education and where it needs improvement.

The chief medical officer of Wave Life Sciences outlined the FOCUS-C9 study, which has incorporated feedback from patients with both ALS and FTD, as well as investigators in the research field.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed employing the MoCA-T app as a means of cognitive screening in rural and ethnically diverse populations.

The potential of a new investigational treatment for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal could offer long-lasting effects for patients.

This NeurologyLive® Peers & Perspectives series features experts in the diagnosis and treatment of Alzheimer disease discussing the recent approval of aducanumab, its implications for Alzheimer disease, and other promising therapies and diagnostic technologies in development.

Here's what is coming soon to NeurologyLive.